Literature DB >> 1348014

Allelic losses at chromosome 17p in human renal cell carcinoma are inversely related to allelic losses at chromosome 3p.

O Ogawa1, T Habuchi, Y Kakehi, M Koshiba, T Sugiyama, O Yoshida.   

Abstract

Recent studies have demonstrated that allelic losses at chromosome 17p are associated with the genesis of a wide variety of human cancers. In order to assess whether the rearrangement of chromosome 17p was responsible for the genesis of renal cell carcinoma (RCC), we used restriction fragment length polymorphism analysis of chromosome 17p. We studied 48 RCCs, including 6 metastatic RCCs, from 43 patients with 5 polymorphic probes to loci within or near the p53 gene. Allelic losses at chromosome 17p were detected in only 6 of the 36 informative cases (17%), and no definitive correlation was demonstrated between allelic losses at 17p and the tumor stages. The 6 RCCs with allelic losses at 17p were histopathologically classified as a clear cell type in one, a mixed cell type in one, and granular cell types in the other four cases. Allelic losses at 17p in the clear cell type of RCC were infrequent (6%, 1 of 18), and were not detected even in the metastatic tumor from a highly advanced case. This finding suggests that allelic losses at 17p could be random genetic rearrangements in the case of the clear cell type of RCC. On the other hand, allelic losses at 17p in the granular cell type of RCC were demonstrated with a significantly higher frequency (44%, 4 of 9). We previously reported that allelic losses at 3p were specific to the clear cell type of RCC (Ogawa et al., Cancer Res., 51:949-953, 1991). Examination of the association of allelic losses at 17p with those at 3p revealed that none of 5 informative RCCs with allelic losses at 17p showed allelic losses at 3p. Conversely, 17 of 25 informative RCCs with retention of 17p alleles lost alleles at 3p. Thus, an inverse relationship was demonstrated with statistical significance (P less than 0.01). These data suggest that the types of rearrangement on chromosome 17p and/or chromosome 3p can differentiate between the histopathological subtypes of RCC.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1348014

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Elevated content of p53 protein in the absence of p53 gene mutations as a possible prognostic marker for human renal cell tumors.

Authors:  G Chemeris; A Loktinov; A Rempel; M Schwarz; P Bannasch
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

2.  Analysis of genetic alterations in renal cell carcinoma using the polymerase chain reaction.

Authors:  Y Suzuki; G Tamura; C Maesawa; T Fujioka; T Kubo; R Satodate
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

3.  Polymerase chain reaction-single strand conformation polymorphism analysis of the p53 gene in paraffin-embedded surgical material from human renal cell carcinomas.

Authors:  Y Kikuchi; T Kishi; M Suzuki; M Furusato; S Aizawa
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

4.  Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays.

Authors:  Meng Chen; Yuanqing Ye; Hushan Yang; Pheroze Tamboli; Surena Matin; Nizar M Tannir; Christopher G Wood; Jian Gu; Xifeng Wu
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

5.  Expression of tumour-suppressor gene Rb, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma.

Authors:  P Lipponen; M Eskelinen; K Syrjänen
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

6.  Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma.

Authors:  Till Eichenauer; Navid Shadanpour; Martina Kluth; Cosima Göbel; Sören Weidemann; Christoph Fraune; Franziska Büscheck; Claudia Hube-Magg; Christina Möller-Koop; Roland Dahlem; Margit Fisch; Michael Rink; Silke Riechardt; Eike Burandt; Christian Bernreuther; Sarah Minner; Ronald Simon; Guido Sauter; Waldemar Wilczak; Till Clauditz
Journal:  World J Surg Oncol       Date:  2020-06-13       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.